Lionel Ades

Paris, 75010, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 239 publications

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Journal: Science translational medicine

Published: July 08, 2026

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Journal: Leukemia

Published: April 14, 2026

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Journal: Leukemia

Published: April 12, 2026

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Journal: Blood cancer journal

Published: March 11, 2026

CPX-351 before allogeneic stem cell transplantation, a real-world French experience.

CPX-351 before allogeneic stem cell transplantation, a real-world French experience.

Journal: Haematologica

Published: March 06, 2026

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

Journal: HemaSphere

Published: October 21, 2025

Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.

Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.

Journal: Leukemia

Published: October 15, 2025

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 25, 2025

Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?

Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?

Journal: Leukemia

Published: September 17, 2025

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 18, 2025

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors.

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors.

Journal: HemaSphere

Published: July 25, 2025

Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.

Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.

Journal: Blood advances

Published: May 06, 2025

Showing 1-12 of 239

Last Updated: 09/26/2026